Senior Vice President, Research and Development @ TCR2, Inc. is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a novel first-in-class approach that is highly differentiated from CAR-T cells and from T cells engineered to express defined TCR alpha/beta chains. TCR2 was founded by MPM Capital and has scientific operations in Kendall Square, Cambridge, MA to leverage best-in-class technologies and nucleate top-tier academic laboratories around the world. From September 2015 to Present (3 months) Vice President, ImmunoOncology @ From June 2014 to September 2015 (1 year 4 months) Senior Director, ImmunoOncology, Head of Translational Immunotherapy @ From March 2012 to June 2014 (2 years 4 months) Senior Director, TA Oncology, Target Research @ From May 2007 to February 2012 (4 years 10 months) Associate Director, Biotherapeutic Discovery @ From October 2005 to April 2007 (1 year 7 months) Program Director, Preclinical Development @ From July 2003 to September 2005 (2 years 3 months) Munich Area, GermanyHead of Lead Pharmacology, Single-Chain Antibodies @ From September 2002 to June 2003 (10 months) Munich Area, GermanyGroup Leader, Protein Drug Design @ From November 1999 to August 2002 (2 years 10 months) Munich Area, GermanyPostdoctoral Research Fellow @ IL-7 Receptor Cytokine Signaling From October 1997 to October 1999 (2 years 1 month)

Doctor of Philosophy (Ph.D.), Immunology, magna cum laude @ Universität Regensburg / University of Regensburg From 1988 to 1999 Robert Hofmeister is skilled in: Cancer Immunotherapy, Oncology, Drug Discovery, Molecular & Cellular Biology, Pharmacology, Life Sciences, Biotechnology, Pharmaceutical Industry, Antibodies, Drug Development, Immunology, Biochemistry, Small Molecules, Cancer Vaccines, Cancer Immune Tolerance, Cancer Inflammation